Horus Pharma's community guidelines

Horus Pharma's community guidelines

This community guidelines’ document is applicable to all social network accounts published by Horus Pharma (YouTube channels, LinkedIn pages, Instagram account, TikTok account and Facebook pages). The purpose of these corporate accounts is to provide the audiences with contextual information on ophthalmology (information, pathology, etc.) and news about Horus Pharma in France.

Horus Pharma is a company with a capital of €2,051,130.20, registered with the Antibes Trade and Companies Register under number 445.317.043 and whose registered office is located at 148 Avenue Georges Guynemer, Cap Var - 06700 Saint Laurent du Var, France.

The Users, hereinafter referred to, are the persons browsing the social networks and websites for which Horus Pharma is responsible.

Acceptance of the Community Guidelines

By browsing or sharing content on Horus Pharma's social network accounts, users acknowledge that they have accepted the present community guidelines and undertake to comply with it.

Horus Pharma may modify these Community Guidelines at any time and without prior notice. The Community Guidelines are accessible at any time and by any User by clicking on the link appearing within the social media account identified as such.

The User acknowledges that they are fully aware of the fact that the information present on Horus Pharma's institutional accounts is neither complete nor exhaustive.

External links

The Horus Pharma Community Guidelines apply only to Horus Pharma social network accounts, and not to websites/social networks owned by third parties. We sometimes provide links to other websites/social networks that we believe may be of interest to the User. At the time of linking, we ensure that these first-degree links comply with our standards. However, due to the facts of the Internet and its changing nature, we cannot be held responsible for the content to which these links direct the User, as the Community Guidelines are not applicable to websites/social networks that are not funded or managed by Horus Pharma.

By clicking on the external links, the User acknowledges and accepts that they are leaving Horus Pharma's account and that they are being redirected to a link external to Horus Pharma, not subject to the conditions of the present Community Guidelines.

Compliance of comments

The Community Guidelines are established in accordance with the applicable regulations and in particular the pharmaceutical regulations and the regulations relating to the protection of personal data to which Horus Pharma is subject.

Certain Horus Pharma accounts offer Users the possibility to comment and make contributions.

Comment moderation consists of monitoring the comments of the Users on the above-mentioned social networks. This monitoring will consist of either:

• reporting messages relating to quality complaints, medical information, or vigilance
• deleting comments

Comments contrary to the provisions of the law must be systematically deleted:

• personal or nominative information (e.g., health professionals, patients, etc.)
• information on treatments and health centres/institutions
• incitement to racial hatred and racist, anti-Semitic, and xenophobic statements
• denial of crimes against humanity and recognized genocides, and apology for war crimes and/or terrorism,
• homophobic or sexist statements,
• statements of a violent, pornographic or pedophile nature,
• defamation and insults between Internet users or towards a third person,
• attacks on privacy or the presumption of innocence, identity theft,
• infringement of copyright and intellectual property rights,
• incitement to commit crimes or offences, apology for drugs,
• calling for murder and incitement to suicide,
• the promotion of an organization recognized as sectarian.

The moderator also reserves the right to delete:

• messages unrelated to the content of the article (off-topic),
• aggressive or rude comments, direct attacks, and insults between Internet users,
• the partial or total resumption of messages posted in the private space of registered users and settling of scores between users on this subject.
• attacks by name on one or more products of the Horus Pharma Laboratory or a competing laboratory,
• criticism of the moderation,
• messages of an openly advertising nature,
• comments that do not respect the victims.
• accounts whose pseudonyms and/or avatars are likely to create confusion with accounts already used on the platform.
• accounts (or posts) that saturate the discussion with an obviously disproportionate number of comments.

Failing this, the User is aware and accepts that his comment may be deleted (for social network accounts that provide for this functionality) or that they may be excluded from Horus Pharma's account in the context of a posteriori moderation.

This a posteriori moderation is carried out within 24 hours from the publication of the comments in accordance with the applicable regulations and Horus Pharma's procedures, in particular the regulations relating to pharmacovigilance/quality, pharmaceutical regulations, regulations relating to the protection of personal data and the Law of 21 June 2004 for Confidence in the Digital Economy (LCEN). This moderation is applicable to Horus Pharma's social network accounts allowing comments/contributions and aims to ensure that these comments comply with the Community Guidelines and, more generally, with the applicable regulations. In particular, it aims to ensure that no quotation and/or direct or indirect reference to a medicine is made in the comments, as information relating to medicinal treatments may be assimilated to advertising within the meaning of article L.5122-6 of the Public Health Code.

The User may not claim any compensation for the moderation of his comments or his exclusion. Moderation does not have to be justified if the moderator considers that a comment should be removed.

All moderated comments are sent to communication@horus-pharma.fr for processing and archiving.

Users who wish to report certain comments published on Horus Pharma's accounts may send a message via the contact: communication@horus-pharma.fr

In addition, Horus Pharma asks Users not to communicate their e-mail address, contact details or other personal information, in particular surname, first name, e-mail address, postal address, telephone number, photo, date of birth, this list not being exhaustive.

Horus Pharma reminds Users that any comment published may be read and used by anyone and may be quoted in other comments.

Furthermore, if the User's comment contains a pharmacovigilance and/or quality observation related to Horus Pharma's products, their consent may be requested to allow Horus Pharma to contact them again and to process information related to its products.

Responsibility

The User is solely responsible for the comments they post, if any, on Horus Pharma's social network accounts.

Horus Pharma assumes the responsibility incumbent upon it in its capacity as publisher of its Horus Pharma social network accounts and in particular its social media manager and the technical service provider appointed in the context of the management of its social network accounts (as defined in article 6 of the Law for Confidence in the Digital Economy).

The User acknowledges in this respect that Horus Pharma:

• does not assume any responsibility for the quality and legal conformity of the content, whatever it may be (texts, sounds, videos, graphics, photos or other) published by the Users,
• may, in accordance with its legal obligations, delete such content after a third party has claimed that the content concerned is illegal and, more generally, if such content does not comply with the regulations in force,
• may communicate, in accordance with its legal obligations and upon formal request from the judicial authorities, the elements allowing the identification of the Users who posted this content.

Personal data

Horus Pharma's accounts are not intended to collect personal data. No personal data is required to access or use these accounts.

However, personal data may appear on social network accounts when the User addresses or posts a contribution on Horus Pharma's institutional accounts. This may include profile data (such as surname, first name or other) or data appearing in the content of his contributions.

In addition, if the User's contributions report an adverse reaction, incident or any information related to the safety of one of our products, we will collect it and contact the User again as part of our legal obligations in this regard.

Finally, we use certain features of social network accounts, such as cookies, statistics, and measurement tools.

For more information on this subject and Horus Pharma's commitments on this issue, the User may consult our Personal Data Protection Policy: https://www.horus-pharma.com/gb/content/37-cgv

Vigilances

Horus Pharma's social network accounts are not primarily intended to collect information about adverse events, incidents or any information related to the safety of any of our products. However, Horus Pharma does process this information in relation to its products as part of its legal obligations of pharmacovigilance and other vigilance whether they are transmitted via comments or private messages. Horus Pharma will contact the User (via the social network account) to obtain additional information on the alert.

The User is reminded that if he/she experiences any undesirable effects, he/she should talk to his/her doctor or pharmacist.

The User may also report adverse reactions directly via the national reporting system: Agence nationale de sécurité du médicament et des produits de santé (ANSM) and the network of Regional Pharmacovigilance Centres - Website: www.signalement-sante.gouv.fr

By reporting adverse reactions, you contribute to providing more information on drug safety.

The User wishing to report an adverse effect, incident or any information related to the safety of a Horus Pharma product may contact the Horus Pharma vigilance department via the following e-mail address: vigilance@horus-pharma.fr